Extravasation GuideTissue injury risk of antineoplastic extravasation

Nonvesicant antineoplastic drugs

Drugs classified as “Nonvesicant” in at least one of the three guidelines. Each guideline column shows the class it assigns.

ONS/ASCO 2025ESMO-EONS 2012JSCN/JSMO/JASPO 2024
Aflibercept——Nonvesicant
Arsenic trioxide—Nonvesicant—
Asparaginase—NonvesicantNonvesicant
Bleomycin—NonvesicantIrritant
Bortezomib—NonvesicantNonvesicant
Brentuximab vedotin——Nonvesicant
Carfilzomib——Nonvesicant
Cladribine—NonvesicantNonvesicant
Clofarabine——Nonvesicant
Cyclophosphamide—NonvesicantIrritant
Cytarabine—NonvesicantNonvesicant
Eribulin——Nonvesicant
Etoposide phosphate—Nonvesicant—
Fludarabine—NonvesicantNonvesicant
Gemcitabine—Nonvesicant—
Inotuzumab ozogamicin——Nonvesicant
Interferons—Nonvesicant—
Interleukin-2—Nonvesicant—
Methotrexate—NonvesicantNonvesicant
Monoclonal antibodies—NonvesicantNonvesicant
Nelarabine——Nonvesicant
Pemetrexed—NonvesicantNonvesicant
Pentostatin——Nonvesicant
Raltitrexed—Nonvesicant—
Temsirolimus—NonvesicantNonvesicant
Thiotepa—NonvesicantNonvesicant
Trastuzumab emtansine——Nonvesicant